室管膜下区在胶质母细胞瘤放疗中的作用
该回顾性队列纳入200例接受手术、放疗和化疗的胶质母细胞瘤患者,分析室管膜下区(SVZ)照射剂量与生存的关系。中位无进展生存期为7.2个月,中位总生存期为15.1个月;多变量分析未发现SVZ剂量与生存显著相关,但肿瘤直接接触SVZ者总生存更差。
要点
- 肿瘤接触SVZ是多变量分析中总生存较差的预后因素。
- 同侧或对侧SVZ平均剂量与生存无显著相关。
- KPS<70%和MGMT启动子未甲基化与无进展生存较差相关。
核心结论
- 在本队列多变量分析中,同侧或对侧SVZ平均剂量增加与接受放疗的胶质母细胞瘤患者生存改善无显著相关。
- 肿瘤直接累及SVZ的患者在多变量分析中总生存更差。
研究设计与样本
- 回顾性纳入2009至2020年在本机构接受手术、放疗和化疗三联治疗的200例胶质母细胞瘤患者。
- 勾画SVZ并计算提取剂量体积直方图,按肿瘤与SVZ接触情况分类。
- 采用Kaplan-Meier法进行生存分析,采用单变量和多变量Cox回归分析无进展生存和总生存的预后因素。
主要发现
- 研究组中位无进展生存期为7.2个月,中位总生存期为15.1个月。
- 多变量分析(以同侧SVZ平均剂量为连续协变量)中,KPS<70%和MGMT启动子未甲基化患者的无进展生存显著更差。
- 总生存较短的预后因素包括高龄、较低KPS、MGMT未甲基化、SVZ接触以及活检而非次全或全切除。
- 生存与SVZ剂量之间无显著相关性。
临床怎么用
- 对于肿瘤直接累及SVZ的胶质母细胞瘤患者,可将其视为总生存较差的预后因素。
- 本研究中同侧或对侧SVZ平均剂量增加未显示生存获益,不支持仅以SVZ剂量作为改善生存的放疗策略依据。
局限性
- 本研究为单中心回顾性分析。
- 摘要未报告SVZ剂量与生存分析的具体数值及多变量分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Current glioblastoma (GBM) therapies prolong survival, but overall prognosis is still poor. Irradiation of the subventricular zone (SVZ) has recently been discussed as a promising concept as this tissue harbors stem cells which seem to play a role in the initiation and recurrence of GBM. In this study, we retrospectively examined the relationship of SVZ irradiation dose and survival in a large, homogeneous GBM patient cohort. MATERIALS AND METHODS: We included 200 GBM patients who had been treated at our institution with trimodal therapy (surgery, radiotherapy and chemotherapy) between 2009 and 2020. The SVZ was delineated, and dose-volume histograms were calculated and extracted. Tumors were classified according to their contact with the SVZ. The Kaplan-Meier method was used for survival analysis, and univariable and multivariable Cox regression (MVA) were used to determine prognostic effects on progression-free survival (PFS) and overall survival (OS). RESULTS: Median PFS of the study group was 7.2 months; median OS was 15.1 months. In MVA (with mean dose to the ipsilateral SVZ as a continuous covariable), PFS was significantly lower for patients with a Karnofsky performance status (KPS) < 70% and without MGMT promoter methylation. Factors prognostic for shorter OS were old age, lower KPS, unmethylated MGMT status, SVZ contact and biopsy instead of subtotal- or gross total resection. There was no significant correlation between survival and SVZ dose. CONCLUSION: In this cohort, an increased mean dose to the ipsilateral or contralateral SVZ did not correlate with improved survival in irradiated GBM patients in MVA. Patients whose tumor directly involved the SVZ showed worse OS in MVA.
引用
- Bender K, Träger M, Wahner H, et al. What is the role of the subventricular zone in radiotherapy of glioblastoma patients? Radiother Oncol. 2021. PMID: 33636228. doi:10.1016/j.radonc.2021.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。